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INTRODUCTION 
 Ischemic heart disease (IHD) is a condition in which there is an 
inadequate supply of blood and oxygen to the myocardium; typically 
occurring when there is an imbalance between myocardial oxygen supply 
and demand. Atherosclerotic disease of an epicardial coronary artery  
(or arteries) sufficient to cause a regional fall in myocardial blood flow 
and inadequate perfusion of the myocardium supplied by  the involved 
coronary artery is the most common cause of myocardial ischemia. A 
substantial percentage of patients will progress to myocardial infarction. 
Coronary artery Heart Disease (CHD) is a leading cause of mortality and 
morbidity worldwide. The mortality and morbidity is attributed to the 
development of heart failure and cardiogenic shock in a considerable 
number of cases. 
 Inflammation is a component of various disorders of the human 
body triggered by varying etiologies. Myocardial infarction is not an 
exception to this. Though the triggering event is an occlusion of the 
coronary artery, various studies have proved an inflammatory component 
in the pathogenesis. Neutrophil lymphocyte ratio (NLR) is one among the 
markers for ongoing systemic inflammatory response. In our study we 
aim to see whether there is an association between elevated on admission 
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NLR and occurrence of heart failure in patients with ST- elevation 
myocardial infarction (STEMI).  
 This is a case control study design with patients having acute 
STEMI and developing heart failure taken as the test group and those 
without heart failure taken as the control group. The number of patients 
with an elevated NLR (>3.5) is recorded in each group and statistical 
analysis is used to look for any statistically significant difference between 
the two groups. This will help us for additional risk stratification of the 
patients with acute STEMI.   
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REVIEW OF THE LITERATURE 
Epidemiology of CHD in SEAR and India 
 Cardiovascular disease (CVD) has emerged as the single most 
important cause of death worldwide especially in the previous decade. 
CVD accounts for 20% of all deaths in the South East Asia Region 
(SEAR). CHD was the leading cause of mortality in 2010-responsible for 
10.6% of total reported fatalities, or 1.8 million deaths, and more than 
half of CVD mortality [1]. Over the past few decades the mortality due to 
communicable diseases has decreased. There has been a drastic and 
tremendous increase in the mortality due to non communicable diseases 
with CHD topping the list. 
 In India the age of initial presentation of CHD is almost a decade 
earlier than that in the developed countries. The ratio of IHD to stroke 
mortality in India is significantly higher than the global average, and is 
comparable to that of Western industrialized countries. Together, IHD 
and stroke are responsible for more than one-fifth (21.1%) of all deaths 
and one-tenth of the years of life lost in India (years of life lost is a 
measure that quantifies premature mortality by weighting younger deaths 
more than older deaths).  
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 Nearly 60.5 million disability adjusted life years (DALYs) are lost 
due to CVD in the SEAR, accounting for 10% of all DALYs lost. CHD is 
responsible for 4.6% of the DALYs lost because of CVD, nearly twice as 
high as for stroke. Mortality rates for CVD are increasing in the region. 
Several studies in India and Pakistan suggest substantial morbidity and 
mortality resulting from CHD in this region. In 1990, 1.18 million people 
died in India as a consequence of CHD; by 2010, this number increased 
to an estimated 2.03 million. CVD probably represents 25% of all deaths 
in India. Studies also show that CHD prevalence is higher in men and in 
urban residents. Prevalence of CHD in India recently was estimated at 
more than 10% in urban areas and 4.5% in rural areas. 
The projected number of deaths from 2010 to 2030 is as follows [2]: 
CVD deaths: annual number of all deaths will rise from 15.6 
million in 2010 to 24.2 million in 2030. 
CVD deaths: percentage of all deaths will rise from 30.0% in 2010 
to 32.5% in 2030. 
CHD deaths: percentage of all male deaths will rise from 13.0% to 
14.9% in 2030 
CHD deaths: percentage of all female deaths will rise from 13.1% 
to 14% in 2030. 
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Epidemiology of Heart Failure (HF) 
 HF is a growing problem worldwide, with more than 20 million 
people affected. The overall prevalence of HF in developed countries is 
2% in the adult population. HF prevalence has an exponential pattern, 
rising with age, and affects 6–10% of people over age 65 [3]. The relative 
incidence of HF is lower in women than in men. Women constitute one-
half of the cases of HF because of their longer life expectancy. In North 
America and Europe, the lifetime risk of developing HF is approximately 
one in five for a 40-year-old. The overall prevalence of HF is thought to 
be increasing, in part because of the advances in treatment modalities for 
cardiac disorders are allowing patients to survive longer.  
Epidemiology of HF complicating Acute coronary syndrome (ACS) 
 Although the etiology of HF is protean, coronary heart disease 
(CHD), in particular, acute myocardial infarction (AMI), is among the 
most frequent causes. Recent advances in treatment have greatly 
improved the survival of patients suffering an AMI. This, combined with 
aging of the population, has increased the number of patients living with 
various degrees of myocardial damage being at risk of developing HF. In 
this context, HF is considered the cause and effect of positive changes in 
coronary care during the last two decades. As proof of this, a Global 
Burden of Disease study reported that despite reductions in AMI 
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incidence and improved survival, the prevalence of HF attributed to 
ischemic heart disease has increased during the past 3 decades.  Incidence 
of HF among patients hospitalized for an AMI varies widely among 
earlier studies, reaching up to 50% [4]. Later studies during the 
revascularization era show that HF is a common complication of AMI. 
HF continues to be a frequent complication of AMI both during the acute 
phase and thereafter. The risk of HF is influenced by a constellation of 
factors related to patient characteristics, such as age, co morbidities, and 
AMI type. It is also due to the underuse of early revascularization 
procedures among elderly patients. 
STEMI 
 Acute myocardial infarction (AMI) is a common cardiac ailment in 
hospitalized patients in industrialized countries. In the USA, there is a 
significant decrease in the incidence of acute STEMI [5].  More than half 
of AMI related deaths occurs before the patient reaches the hospital. The 
in-hospital mortality rate has declined from 10% to about 6% over the 
past decade.  Mortality is fourfold higher in elderly patients as compared 
with younger individuals. 
  When patients with acute chest discomfort at rest are first seen, the 
working clinical diagnosis is acute coronary syndrome. The 12-lead 
electrocardiogram (ECG) is a pivotal diagnostic and triage tool; it permits 
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distinction of those patients presenting with ST-segment elevation from 
those presenting without ST-segment elevation. Serum cardiac 
biomarkers are obtained to distinguish unstable angina (UA) from non-
ST-segment elevation myocardial infarction (NSTEMI) and to assess the 
magnitude of an ST-segment elevation myocardial infarction. 
Pathogenesis of STEMI 
  STEMI occurs when coronary blood flow decreases abruptly after 
a thrombotic occlusion of a coronary artery previously affected by 
atherosclerosis. Slowly developing, high-grade coronary artery stenosis  
typically do not precipitate STEMI because of the development of a rich 
collateral arterial supply over time.. STEMI occurs when a coronary 
artery thrombus develops rapidly at a site of plaque disruption .This 
injury is  facilitated and propagated by factors such as cigarette smoking, 
hypertension, and lipid accumulation.  
 In most cases, STEMI occurs when the surface of an 
atherosclerotic plaque is disrupted (exposing its contents to the blood) 
and when conditions favour thrombogenesis. A mural thrombus is formed 
at the site of plaque disruption, and the involved coronary artery gets 
occluded.  
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 Several studies indicate that the coronary plaques prone to 
disruption are those with a rich lipid core and a thin fibrous cap. After an 
initial platelet monolayer forms at the site of plaque disruption, various 
agonists (collagen, ADP, epinephrine, serotonin) promote platelet 
activation. After agonist stimulation of platelets, thromboxane A2 which 
is a potent local vasoconstrictor is released. Platelet activation is 
augmented further. In addition a potential resistance to fibrinolysis 
develops. A conformational change in the glycoprotein IIb/IIIa receptor 
occurs. This receptor has a high affinity for soluble adhesive proteins 
such as fibrinogen. Fibrinogen is a multivalent molecule and it can bind 
to two different platelets simultaneously, resulting in platelet cross-
linking and aggregation.  
 The coagulation cascade is activated on exposure of tissue factor in 
damaged endothelial cells at the site of plaque disruption. Factors VII and 
X are activated, ultimately leading to the conversion of prothrombin to 
thrombin, which then converts fibrinogen to fibrin. Fluid-phase and clot-
bound thrombin participates in an auto amplification reaction leading to 
further activation of the coagulation cascade. The affected coronary artery 
finally becomes occluded by a thrombus containing platelet aggregates 
and fibrin strands. In rare cases, STEMI may be due to coronary artery 
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occlusion caused by coronary emboli. Congenital abnormalities, coronary 
spasm, and vasculitic disorders are rare causes of STEMI.  
FACTORS AFFECTING THE EXTENT OF MYOCARDIAL 
DAMAGE 
The amount of myocardial damage depends on 
 the territory supplied by the affected vessel 
  partial or complete occlusion of the vessel 
  the duration of  occlusion 
 the extent of collateral blood flow to the affected tissue 
 the myocardial oxygen demand 
 endogenous factors that can produce early spontaneous lysis of the 
occlusive thrombus 
  The adequacy of myocardial perfusion in the infarct zone when 
flow is restored in the occluded epicardial coronary artery. 
RARE CAUSES OF STEMI 
Rare medical conditions predisposing patients to STEMI include: 
 hypercoagulability 
  collagen vascular disease 
  cocaine abuse 
  intracardiac thrombi or masses that can produce coronary 
emboli. 
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Definition of Myocardial Infarction 
Criteria for Acute Myocardial Infarction 
The term acute myocardial infarction (MI) should be used when 
there is evidence of myocardial necrosis in a clinical setting consistent 
with acute myocardial ischemia. Under these conditions, any one of the 
following criteria meets the diagnosis for MI: 
• Detection of a rise and/or fall of cardiac biomarker values 
(preferably cardiac troponin [cTn]) with at least one value above 
the 99th percentile upper reference limit (URL) and with at least 
one of the following: 
• Symptoms of ischemia 
• New or presumed new significant ST-segment T-wave (ST-T) 
changes or new left bundle branch block (LBBB) 
• Development of pathologic Q waves in the electrocardiogram 
(ECG) 
• Imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormality 
• Identification of an intracoronary thrombus by angiography or 
autopsy 
• Cardiac death with symptoms suggestive of myocardial ischemia 
and presumed new ischemic ECG changes of new LBBB, but death 
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occurred before cardiac biomarkers were obtained or before 
cardiac biomarker values would be increased. 
• Percutaneous coronary intervention (PCI)–related MI is arbitrarily 
defined by elevation of cTn values (>5 × 99th percentile URL) in 
patients with normal baseline values (≤99th percentile URL) or a 
rise of cTn values >20%, if the baseline values are elevated and are 
stable or falling. In addition, either  
o symptoms suggestive of myocardial ischemia, or  
o new ischemic ECG changes, or 
o angiographic findings consistent with a procedural  
o complication, or imaging demonstration of new loss of  
viable myocardium or new regional wall motion abnormality  
are required. 
• Stent thrombosis associated with MI when detected by coronary 
angiography or autopsy in the setting of myocardial ischemia and 
with a rise and/ or fall of cardiac biomarker values with at least one 
value above the 99th percentile URL. 
• Coronary artery bypass grafting (CABG)–related MI is arbitrarily 
defined by elevation of cardiac biomarker values (>10 × 99th 
percentile URL) in patients with normal baseline cTn values (≤99th 
percentile URL). In addition, either (i) new pathologic Q waves or 
new LBBB, or (ii) angiographic documented new graft or new 
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native coronary artery occlusion, or (iii) imaging evidence of new 
loss of viable myocardium or new regional wall motion 
abnormality. 
 
Criteria for Prior Myocardial Infarction 
Any one of the following criteria meets the diagnosis for prior MI: 
• Pathologic Q waves with or without symptoms in the absence of 
non ischemic causes. 
• Imaging evidence of a region of loss of viable myocardium that is 
thinned and fails to contract, in the absence of a non ischemic 
cause.  
 
Echocardiography in Acute Coronary Syndrome 
  Ventricular systolic function can be assessed by echocardiography 
using various methods. In the most commonly used method for assessing 
systolic function, .the LV ejection fraction (LVEF) is calculated as the 
difference between end-diastolic volume and end-systolic volume divided 
by end-diastolic volume. It is a useful tool in diagnosis and risk 
stratification in a variety of cardiovascular diseases. Accurate assessment 
of LVEF requires calculation from ventricular volumes but many 
echocardiography laboratories estimate LVEF visually. Even though 
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calculation of LVEF from volumes is preferred, the accuracy of this 
estimation is affected by image quality like endocardial border definition, 
ventricular geometry, and representative orthogonal imaging planes. 
When the above mentioned factors are suboptimal, visual estimation by 
experienced echocardiographers can be more accurate and sufficient for 
most clinical scenarios.  
 Echocardiography plays an important diagnostic and prognostic 
role in monitoring patients during and after acute MI. Normal wall 
contractility (normokinesis) is visualised as wall thickening produced by 
the contraction of individual myocardial fibers during systole. On 
echocardiography the radial distance between the epicardial and 
endocardial borders normally increases by at least 20% during systole. 
 Global LVEF, as calculated by two-dimensional echocardiography 
and preferably by the two-dimensional biplane method of discs, provides 
an indication of overall infarct size and location. It is the single measure 
with the greatest prognostic and clinical significance during and 
following MI. Myocardial ischemia affects LV systolic function both 
focally and globally. Focal hypokinesis-decreased systolic thickening- 
occurs within seconds of the onset of myocardial ischemia, before chest 
pain and changes on the ECG and is the pathognomonic finding occurring 
in the region of the left and/or right ventricle supplied by the 
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compromised artery (at least 70% stenosis) and gives the appearance of a 
hinge point when compared with adjacent perfused segments. Ischemia 
may also be manifested as delayed contractility of a segment. Ischemia is 
a dynamic condition, and if sufficient blood flow is restored in time, 
contractility of the affected segment can recover rapidly. However, in the 
setting of reperfusion therapy, a marked reduction in LVEF during the 
initial few days after MI can be secondary to myocardial stunning, 
myocardial dysfunction and can improve substantially over a period of 
days to weeks. 
 Persistence or increasing severity of the wall motion abnormality 
after the initial insult implies that the tissue is becoming non-functional 
(i.e., not metabolically active or hibernating) or nonviable (infarcted). 
Akinetic myocardial segments do not thicken at all. Dyskinetic segments 
bulge paradoxically outward in systole, thus implying that no functioning 
myocardium is present. Thinning of the walls to less than 6 mm, 
echobrightness, and dyskinesis usually indicate scar. Sudden dilation of 
the left ventricle and a decrease in the LVEF are predictive signs of larger 
areas of ischemia (more proximal and/or multivessel).  
 More refined techniques like intravenous echocardiographic 
contrast enhancement to examine myocardial perfusion, low-dose 
dobutamine echocardiography, or regional strain analysis, may be useful 
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in demonstrating whether segments that are still akinetic after reperfusion 
remain viable. But hibernating LVEF is one of the most important 
predictors of overall morbidity and mortality after acute MI and is used as 
a surrogate endpoint. As LVEF declines, the rate of sudden cardiac death 
(SCD) increases.  
  As mentioned previously, it is important to recognize that 
functional recovery of stunned myocardium can occur after reperfusion 
and lead to an improvement in LVEF when measured 2 to 6 weeks after 
revascularization. In addition to LVEF, overall LV size and sphericity are 
important prognostic indicators. Other measures that are independently 
predictive of heart failure in patients with stable CAD include increasing 
LV mass index (LVMI >90 g/m2), a pseudo normalized or restrictive 
pattern of diastolic dysfunction, an LVOT VTI of less than 22 mm, and 
an LA volume index higher than 29 ml/m2. The presence of even mild 
MR is also an independent predictor of cardiac mortality, as well as heart 
failure or recurrent MI.  
 The WMSI may be a more discriminatory measure than LVEF (as 
measured by echocardiography or nuclear methods) in predicting cardiac 
events. On resting echocardiography, a WMSI higher than 1.7 that 
persists after treatment of MI suggests a substantial (>20%) perfusion 
defect and increased risk for complications. In stress echocardiography, a 
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WMSI higher than 1.7 at peak stress and an ejection fraction of 45% or 
less are independent markers of patients at high risk for recurrent MI or 
cardiac death. When there is a question of whether revascularization will 
improve akinetic but viable areas, dobutamine or contrast enhanced 
echocardiography may delineate the extent of myocardium that is 
hibernating (hypocontractile yet viable and still perfused). 
 Heart failure (HF) is a complex clinical syndrome occurring due 
to structural and functional impairment of ventricular filling or ejection of 
blood. Although HF can develop as a consequence of abnormalities or 
disorders involving all aspects of cardiac structure and function, 
significant number of patients have reduced myocardial performance, 
with findings ranging from normal ventricular size and function to 
marked dilation and reduced function. 
Although symptoms of HF frequently depend on the presence of 
elevated left- or right-sided heart filling pressures, the designation 
“congestive” in this context is no longer preferred, because many patients 
do not have overt congestion at the time of evaluation. About fifty 
percent of the patients with HF have normal left ventricular function, that 
is, HF with preserved ejection fraction (HFpEF) ; the rest of them have 
HF with reduced ejection fraction (HFrEF). HFpEF generally is defined 
as a left ventricular ejection fraction of 50% or greater, whereas 
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HFrEF is defined as an ejection fraction below 40%. These 
distinctions are important in planning treatment strategies for treating. 
 There are two recognized useful methods to classify patients with 
HF. The American College of Cardiology/American Heart Association 
(ACC/AHA) HF staging approach emphasizes the importance of 
development and progression of disease, whereas the New York Heart 
Association (NYHA) functional classification focuses more on exercise 
tolerance in persons with established HF. The NYHA functional 
classification is commonly used. It is associated with subjective 
variability.  
 American College of Cardiology/American Heart Association 
(ACC/AHA) Stages of Heart Failure (HF) Compared with the New York 
Heart Association (NYHA) Functional Classification 
 
ACC/AHA STAGES NYHA FUNCTIONAL CLASSIFICATION 
A)  At high risk for HF but without structural heart disease or HF  
 symptoms 
None 
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B)  Structural heart disease but without signs or symptoms of HF 
I. No limitation of physical activity. Ordinary physical activity  
     does not cause symptoms of HF 
C) Structural heart disease with previous or current symptoms of HF 
I. No limitation of physical activity Ordinary physical activity does  
      not cause symptoms of HF 
II. Slight limitation of physical activity. Comfortable at rest, but  
          ordinary physical activity results in symptoms of HF 
III. Marked limitation of physical activity Comfortable at rest, but  
           less than ordinary activity causes symptoms of HF 
D)  Refractory HF requiring specialized interventions 
IV. Unable to carry on any physical activity without symptoms of  
       HF, or symptoms of HF at rest 
Echocardiography  
Transthoracic echocardiography is an important part of the 
evaluation of HF. The major advantages are as follows 
1. There no additional risk to the patient during echo. 
2. It is not associated with radiation exposure. 
3. It can be performed at the bedside in emergency situations.  
19 
 
4. It is particularly more useful in assessing the structure and function 
of both the myocardium and heart valves and in providing 
information about intracardiac pressures 
 
The initial evaluation of the patient with AHF focuses on the 
following critical aspects:  
 
1. early and  definitive diagnosis of AHF as rapidly and efficiently as 
possible 
2. Immediate treatment for potentially life-threatening conditions 
(e.g., shock, respiratory failure) 
3. Identifying and addressing any relevant clinical triggers 
4. Risk stratification for triage of the patient to an appropriate level of 
care (e.g., intensive care unit, telemetry unit, observation unit) 
5. Defining the clinical profile of the patient (based on blood 
pressure, volume status, and renal function) to allow rapid 
implementation of the most appropriate therapy. 
 
The term acute MI should be used when there is evidence of 
myocardial necrosis in a clinical setting consistent with acute myocardial 
ischemia. Under these conditions any of the following criteria meet the 
diagnosis for MI [7]: 
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• Detection of a rise and/or fall in cardiac biomarker values 
(preferably cTn), with at least one value above the 99th percentile 
of the URL and with at least one of the following: 
• Symptoms of ischemia 
• New or presumed new significant ST-segment T wave (ST-T) 
changes or new LBBB 
• Development of pathologic Q waves on the ECG 
• Imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormality 
• Identification of an intracoronary thrombus by angiography or 
autopsy 
 Clinical diagnosis of MI requires a clinical syndrome indicative of 
myocardial ischemia with some combination of evidence of myocardial 
necrosis on biochemical, electrocardiographic, or imaging modalities 
 If a significant amount of myocardium undergoes ischemic injury 
LV pump function becomes depressed; cardiac output, stroke volume, 
blood pressure, and peak dP/dt decline; and end-systolic volume 
increases. The degree to which end-systolic volume increases is perhaps 
the most powerful hemodynamic predictor of mortality following 
STEMI. Paradoxical systolic expansion of an area of ventricular 
myocardium causes further fall in LV stroke volume. 
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ELECTROCARDIOGRAPHIC CHANGES ASSOCIATED WITH 
PREVIOUS MYOCARDIAL INFARCTION (IN THE ABSENCE 
OF LEFT VENTRICULAR HYPERTROPHY AND LEFT 
BUNDLE BLOCK) 
 Any Q wave in leads V2-V3 ≥0.02 sec or a QS complex in 
leads V2 and V3 
 Q wave ≥0.03 sec and ≥0.1-mV deep or QS complex in 
leads I, II, aVL, aVF, or V4-V6 in any 2 leads of a 
contiguous lead grouping (I, aVL; V1-V6; II, III, aVF) 
 R wave ≥0.04 sec in V1-V2 and R/S ≥1 with a concordant 
positive T wave in absence of a conductions defect 
 
Left Ventricular Failure 
 Left ventricular dysfunction is the single most important predictor 
of mortality following STEMI. In patients with STEMI, either systolic 
dysfunction alone or both systolic and diastolic dysfunction can occur. 
Left ventricular diastolic dysfunction results in pulmonary venous 
hypertension and pulmonary congestion. Clinical manifestations of left 
ventricular failure become more common as the extent of injury to the left 
ventricle increases. In addition to infarct size, other important predictors 
of the development of symptomatic left ventricular dysfunction include 
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advanced age and diabetes. There is a direct relationship between the 
mortality and the severity of the hemodynamic deficit [8]. 
THERAPEUTIC IMPLICATIONS 
 Classification of patients with STEMI by hemodynamic subsets 
has therapeutic relevance. As already noted, patients with normal wedge 
pressure and hypoperfusion may benefit from intravenous  fluids because 
the peak stroke volume value is not usually achieved until left ventricular 
filling pressure reaches 18 to 24 mm Hg. However, a low level of left 
ventricular filling pressure does not necessarily imply that the left 
ventricular damage is slight. Such patients may be relatively hypovolemic 
and/or may have suffered a right ventricular infarct with or without 
severe left ventricular damage. The relationship between ventricular 
filling pressure and cardiac index when preload is increased by infusion 
of fluid can provide valuable hemodynamic information in addition to 
that obtained from baseline measurements. For example, the ventricular 
function curve rises steeply (marked increase in cardiac index, small 
increase in filling pressure) in patients with normal left ventricular 
function and hypovolemia, whereas the curve rises gradually or remains 
flat in patients with a combination of  hypovolemia and depressed cardiac 
function. Invasive hemodynamic monitoring can help guide therapy in 
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patients with severe left ventricular failure (pulmonary capillary wedge 
pressure >18 mm Hg and cardiac index <2.2 litres / min / m2). 
 In patients with STEMI heart failure is best managed first by 
reducing ventricular preload and then, if possible, by lowering afterload. 
Positive inotropic agents can be useful, but they cannot be used as the 
initial therapy of choice. Any arrhythmia should be treated promptly in 
patients with left ventricular failure, as they can contribute to 
hemodynamic compromise. 
CARDIOGENIC SHOCK 
 Cardiogenic shock is the worst clinical presentation of left 
ventricular failure. It occurs when there is extensive damage to the left 
ventricular myocardium. More than 80% of STEMI patients have 
extensive damage to left ventricle and so develop cardiogenic shock 
during the course, even with prompt management.  
Assessment of Left Ventricular Function 
 The left ventricular ejection fraction may be the most easily 
assessed measurement of left ventricular function and is extremely useful 
for risk stratification. However, imaging of the left ventricle at rest may 
not adequately distinguish among infarcted, irreversibly damaged, and 
stunned or hibernating myocardium. To circumvent this difficulty, 
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various techniques have been investigated to assess the extent of residual 
viable myocardium 
PROGNOSIS 
 Despite many recent advances in the evaluation and management 
of HF, the development of symptomatic HF still carries a poor prognosis. 
Community-based studies indicate that 30–40% of patients die within 1 
year of diagnosis and 60–70% die within 5 years, mainly from worsening 
HF or as a sudden event (probably because of a ventricular arrhythmia). 
Although it is difficult to predict prognosis in an individual, patients with 
symptoms at rest (New York Heart Association [NYHA] class IV) have a 
30–70% annual mortality rate, whereas patients with symptoms with 
moderate activity (NYHA class II) have an annual mortality rate of  
5–10%. Thus, functional status is an important predictor of patient  
outcome [9] 
VENTRICULAR DYSFUNCTION 
 After STEMI, there occurs a series of changes in shape, size, and 
thickness in both the infarcted and non infarcted segments in the left 
ventricle. This process is referred to as ventricular remodelling and 
generally precedes the development of clinically evident CHF. 
Immediately after STEMI, the left ventricle begins to dilate. Acutely, 
these results from expansion of the infarct, i.e., slippage of muscle 
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bundles, disruption of normal myocardial cells, and tissue loss within the 
necrotic zone, resulting in disproportionate thinning and elongation of the 
infarct zone. Later, lengthening of the non infarcted segments also occurs. 
The overall chamber enlargement that occurs is related to the size and 
location of the infarct. Infarction of the anterior wall and apex of the left 
ventricle is associated with greater dilation of left ventricle. And it results 
in significant hemodynamic impairment, more frequent heart failure, and 
a poorer prognosis. Progressive dilation and its clinical consequences 
may be ameliorated by therapy with ACE inhibitors and other 
vasodilators (e.g., nitrates). In patients with an ejection fraction <40%, 
regardless of whether or not heart failure is present, ACE inhibitors or 
ARBs should be prescribed  
HEMODYNAMIC ASSESSMENT 
 Hemodynamic evidence of abnormal global LV function appears 
when contraction is significantly reduced in 20–25% of the left ventricle. 
Patient develops cardiogenic shock when there is infarction of ≥40% of 
the left ventricle. 
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POST INFARCTION RISK STRATIFICATION AND 
MANAGEMENT 
 There are many clinical and laboratory factors have been that are 
related with an increase in cardiovascular risk after initial recovery from 
STEMI. Some of the most important factors include persistent ischemia 
(spontaneous or provoked), depressed LV ejection fraction (<40%), 
rales above the lung bases on physical examination. Evaluation of LV 
function is usually warranted as well. Recognition of a depressed LV 
ejection fraction by echocardiography or radionuclide 
ventriculography identifies patients who should receive medications 
to inhibit the renin-angiotensin-aldosterone system. Patients who 
have a depressed ejection fraction, should be considered at high risk 
for recurrent MI or death from arrhythmia.  Cardiac catheterization 
with coronary angiography and/or invasive electrophysiologic evaluation 
is advised. 
EJECTION FRACTION (%) 
normal LV function -      ≥55 
 mild LV dysfunction -      45-54  
 moderate LV dysfnction -   30-44  
 Severe LV dysfunction -    <30 
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NEUTROPHIL TO LYMPHOCYTE RATIO AS A 
INFLAMMATORY MARKER IN CVD 
 Raised levels of inflammation are related with a poor prognosis in 
CAD. Inflammation plays a vital role in the development of heart failure. 
Inflammatory stimuli result in release of the inflammatory cytokines TNF 
alpha, IL -6, AND CRP, also some proteolytic enzymes. These pro-
inflammatory  cytokines have destructive effects on the myocardium, 
resulting in impaired LV performance and HF. Prior studies in this field 
have demonstrated that elevated levels of pro inflammatory cytokines 
may result in myocardial remodelling and cardiac arrhythmias 
.Lymphocytes play an important role in healing by modulating  
mononuclear cell phenotypes and activating the tissue inhibitor of 
metalloproteinase – 1 expression.  Lymphopenia is more common in 
stressful conditions due to hypothalamo- pitutery – adrenal axis. The 
activation of this axis leads to cortisol production and increased cortisol 
results In decrease in the   relative lymphocyte levels. Lymphopenia is an 
independent prognostic factor and is also associated with decreased 
survival in heart failure patients. 
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NLR 
 The neutronphil to lymphocyte ratio [NLR] is a novel simple 
biomarker of inflammation. It has emerged as a predictor of poor 
prognosis in cancer and cardiovascular disease. Here we investigated the 
association between NLR and heart failure in acute ST elevation MI. 
NLR is obtained by dividing absolute neutrophil count to lymphocyte 
count. NLR is a simple and in expensive index in assessing inflammation.  
Previous studies have demonstrated the predictive value of NLR as a 
novel inflammatory marker in patients with cardiovascular diseases In 
patients with hypertension elevated NLR has a positive correlation with 
hyperhomocysteinemia also plays as a marker of inflammation in the 
development of aneurysm of ascending aorta. Increased NLR value was 
an independent variable for carotid artery plaques to become 
symptomatic. A dynamic change of NLR has been shown to predict the 
hemorrhagic transformation in ischemic stroke. In patients undergoing no 
urgent percutaneous coronary intervention, a higher NLR was associated 
with periprocedural MI. Elevated NLR is associated with worse overall 
survival in cancer patients. Meanwhile Durmus et al. found that higher 
NLR value can predict the death in advanced heart failure. NLR, a novel 
biomarker for assessing inflammation, has been getting widely used to 
identify patients with various illnesses. It is a biomarker that integrates 
two WBC subtypes representing two inversely related immune pathways. 
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It was easily calculated from differential WBC counts, less affected by 
conditions that could affect the individual counts. NETosis, first 
discovered in 2004 by Brinkmann et al, is a inflammatory process in 
which activated neutrophils form Neutrophil extracellular traps [NETS],  
in which the nuclear material is  released into the extracellular space 
including the DNA, citrulinnated histones, and enzymes of neutrophil 
granules. This discovery casts a new light on the role of neutrophils in 
nonspecific immune response of the body. NETs may promote 
inflammatory reactions that cause tissue damage. Circulating cell free 
DNA, a marker of NETs also augments inflammation. All these suggest 
formation of NETs may be one of the possible mechanisms by which an 
increased NLR is related to higher mortality. 
 
 
 
 
  
  
 
 
 
 
AIMS  
AND  
OBJECTIVES 
  
30 
 
AIMS & OBJECTIVES: 
 To investigate the association between on admission NLR and heart 
failure in acute ST elevation myocardial infarction. 
DETAILS OF THE STUDY 
Study design:- 
           Case control study, a secondary data analysis of case sheets over 2 
months 
Study period:-  2 months  
Study area:- Govt. Royapettah Hospital, Chennai. 
 Study population:- 
          Patients with acute ST elevation myocardial infarction with and 
without heart failure 
Ethical clearance:- 
 Ethical committee clearance was obtained. 
Consent:- 
     Informed consent obtained from all subjects. Patient confidentiality 
maintained. 
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SAMPLE SIZE:-  
            Case control study, a secondary data analysis of case sheets over 2 
months. 110 cases of acute STEMI (55 with heart failure and 55 without 
heart failure) are required to identify the association between elevated NLR 
and heart failure in acute STEMI at 95% confidence interval and when the 
percentage of acute STEMI without heart failure with elevated NLR is 46% 
and the difference between the two is 30%  
INCLUSION CRITERIA:-  
All patients with acute ST elevation myocardial infarction with and 
without heart failure. 
 
EXCLUSION CRITERIA:- 
 Clinical evidence of active infection 
 End stage liver disease 
 End stage kidney disease 
 Hematological diseases 
 Systemic autoimmune diseases 
 Malignancies 
 Acute Non- STEMI 
  
 
 
 
 
METHODOLOGY 
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METHODOLOGY 
        In my study a secondary data analysis of case sheets was done. On 
admission NLR (normal NLR is 1.8-3.5) is calculated from complete 
blood count taken within one hour of admission in patients with and 
without heart failure getting admitted to the intensive coronary care unit 
with acute ST- elevation myocardial infarction taking a sample size of 55 
in each group. ST elevation MI is defined as > 0.2mV in V2 – V3, > 0.1 
mV in all other leads. A comparison of NLR will be made between those 
with and without heart failure. This study will help us to know the 
association of NLR and occurrence of heart failure in those with acute ST 
elevation myocardial infarction. This will help us for additional risk 
stratification of the patients with acute STEMI. 
 110 cases of acute STEMI (55 with heart failure and 55 without 
heart failure) are required to identify the association between elevated 
NLR and heart failure in acute STEMI at 95% confidence interval and 
when the percentage of acute STEMI without heart failure with elevated 
NLR is 46% and the difference between the two is 30%. At KMC on an 
average 4 cases of AMI per day gets admitted with 40% developing heart 
failure. To get 55 cases of heart failure it would require roughly  
2 months. 
CONFLICT OF INTEREST: NIL 
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DATA ANALYSIS 
 Data was collected using predesigned proforma. The study population 
consisted of 110 hospitalised patients admitted to the intensive coronary care 
unit with acute STEMI, with both males and females included in the study. A 
complete blood count was done within one hour of admission in the study 
population and the total neutrophil and lymphocyte count was taken for data 
analysis. A neutrophil to lymphocyte ratio was calculated. Those patients with 
STEMI progressing to heart failure based on echocardiography criteria were 
the test (cases) group. The NLR of the test group was compared with the 
control group without heart failure.  
STATISTICS 
 The collected data were analysed with IBM.SPSS statistics 
software 23.0 Version. To describe about the data descriptive statistics 
frequency analysis, percentage analysis were used for categorical 
variables and the mean & S.D were used for continuous variables. To find 
the significant difference between the bivariate samples in Independent 
groups (Cases & Controls) the unpaired sample t-test was used .To find 
the significance in categorical data Chi-Square test was used. In both the 
above statistical tools the probability value .05 is considered as 
significant level.  
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 P value- Highly significant at P < or = 0.01 
          P value- Significant at 0.01 < P < or = 0.05 
 P value- Not Significant at P > 0.05 
                                                     
  
  
 
 
 
 
RESULTS 
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RESULTS 
DESCRIPTIVE STATISTICAL ANALYSIS 
Frequencies 
Frequency Tables 
AGE 
 
 
 
 
 
 
 
 
 
 
 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
31 - 40 yrs 41 - 50 yrs 51 - 60 yrs Above 60
yrs
8.2
30.0
58.2
3.6
Age range
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AGE 
  Frequency Percent 
Valid 31 - 40 yrs 9 8.2 
41 - 50 yrs 33 30.0 
51 - 60 yrs 64 58.2 
Above 60 yrs 4 3.6 
Total 110 100.0 
 
 
 
 
 In our study the minimum age of the sample was 35 years and the 
maximum age was 70 years. From the above frequency distribution it is 
seen that the majority of the patients, 58.2% are in the 51-60 years range. 
It can also be seen that the frequency of acute STEMI in our study sample 
is more common in the fourth and fifth decades of life. The mean age of 
the affected study sample is 55 years with a standard deviation of  
3.6 years. 
Descriptive Statisticsa 
  N Minimum Maximum Mean 
Std. 
Deviation 
AGE 31 48 63 55.19 3.637 
Valid N 
(list wise) 
31 
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28%
72%
Gender distribution
Female Male
SEX 
 
  Frequency Percent 
Valid 
Female 31 28.2 
Male 79 71.8 
Total 110 100.0 
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        The total number of females in the entire study sample is 31. There 
were 79 male patients. More than two third of cases were males. From 
our sample it is clear that acute STEMI is much more common in males 
as compared to females. The mean age of the affected female was 55 with 
a standard deviation of 3.6 years. The mean age of the affected male was 
51 years with a standard deviation of 7.1 years. 
 
 
Descriptive Statisticsa 
  N Minimum Maximum Mean 
Std. 
Deviation 
AGE 31 48 63 55.19 3.637 
Valid N  
(list wise) 
31     
 
a. SEX = F 
Descriptive Statisticsa 
  N Minimum Maximum Mean 
Std. 
Deviation 
AGE 79 35 70 51.34 7.186 
Valid N  
(list wise) 
79     
 
a. SEX = M 
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T-Test 
     
 An analysis of the group statistics of the distribution of all the 
variables between the two groups is depicted in the above table. The 
mean age of the patients among the cases is 53.65+/- 6.43. The mean age 
of the patients among the control group is 51.2+/- 6.59. Both groups are 
comparable in this aspect with no gross discrepancy in the ages of the two 
groups. 
Group Statistics 
Groups N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
AGE 
Cases 55 53.65 6.438 .868 
Controls 55 51.20 6.598 .890 
Total count/cmm 
Cases 55 8106.36 1204.398 162.401 
Controls 55 7551.45 1267.027 170.846 
Neutrophil count 
Cases 55 5873.02 1029.278 138.788 
Controls 55 5019.80 905.594 122.110 
Lymphocyte count 
Cases 55 1673.38 391.974 52.854 
Controls 55 1803.25 466.878 62.954 
Neutrophil/Lymphocyte 
ratio 
Cases 55 3.617 .7356 .0992 
Controls 55 2.868 .5808 .0783 
Ejection Fraction % 
Cases 55 37.00 7.167 .966 
Controls 55 61.16 4.289 .578 
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 The ejection fraction of the patients in the two groups is 
significant. The mean EF is 37+/- 7.16 in the test group with heart failure. 
The mean EF is 61+/-4.28 in the control group without heart failure.  
 The mean neutrophil count of the cases was 5873 with a standard 
deviation of 1029. The mean neutrophil count of the control group was 
5019.8 with a standard deviation of 905.59.  
 Similarly the mean lymphocyte count of the test group was 
1673.38 with a standard deviation of 392. The mean lymphocyte count of 
the control group was 1803.25 with a standard deviation of 467. 
 The mean neutrophil to lymphocyte ratio in the control group was 
2.868 with a standard deviation of 0.58.This falls well within the normal 
range of NLR among the controls. The mean NLR of the test group was 
3.617 with a standard deviation of 0.73. The mean NLR of the test group 
i.e., for patients with acute STEMI and heart failure falls outside the 
normal rangee with majority of the patients having an elevated NLR. Our 
aim is to assess whether this is statistically significant between the two 
groups. This is done by using the unpaired t-test. 
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 It is evident from the above table that the P value for the age 
distribution between the two groups is not statistically significant. The 
distribution of the total count value between the two groups is significant 
as the P value is 0.020. The lymphocyte count between the two groups is 
not statistically significant as the P value is 0.117. The neutrophil count 
between the two groups is statistically highly significant as the P value is 
0.0005. Similarly as evidenced by the distribution of NLR values between 
the two groups in the previous table there is a highly statistically 
significant difference between the two groups with elevated NLR seen in 
Independent Samples Test 
  
t-test for Equality of Means 
t df 
Sig.  
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
AGE   1.975 108 .051 2.455 1.243 
Total 
count/cmm 
  2.354 108 .020 554.909 235.717 
Neutrophil 
count 
  4.615 108 .0005 853.218 184.859 
Lymphocyte 
count 
  -1.580 108 .117 -129.873 82.199 
N/L ratio   5.927 108 .0005 .7491 .1264 
Ejection 
Fraction % 
  -21.454 88.283 .0005 -24.164 1.126 
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patients developing or presenting with heart failure as compared to the 
control group. As is part of any comparative statistical analysis it is 
mandatory to ensure comparability between the two groups by assessing 
the categorical data for significance between the two groups. This is done 
by the Chi-Square test. 
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Cross tabs- AGE * Groups 
      Crosstab 
  
Groups 
Total 
Cases Controls 
AGE 31 - 40 yrs Count 
 
3 6 9 
% within 
Groups 
 
5.5% 10.9% 8.2% 
41 - 50 yrs Count 16 17 33 
% within 
Groups 
 
29.1% 30.9% 30.0% 
51 - 60 yrs Count 
 
32 32 64 
% within 
Groups 
 
58.2% 58.2% 58.2% 
Above 60 yrs Count 
 
4 0 4 
% within 
Groups 
 
7.3% 0.0% 3.6% 
Total Count 
 
55 55 110 
% within 
Groups 
100.0% 100.0% 100.0% 
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Cross tabs- AGE * Groups 
       
 
 
 
 
          
Chi-Square Tests 
  Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 5.030a 3 .170 
Likelihood Ratio 6.595 3 .086 
Linear-by-Linear 
Association 
2.266 1 .132 
N of Valid Cases 110     
a. 4 cells (50.0%) have expected count less than 5. The 
minimum expected count is 2.00. 
 
 
 
 
 
Cases Controls 
31 - 40 yrs 5.5% 10.9% 
41 - 50 yrs 29.1% 30.9% 
51 - 60 yrs 58.2% 58.2% 
Above 60 yrs 7.3% 0.0% 
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 It is clear from the above cross tabs that the ages are distributed 
equally between both groups in all ranges. The Chi-Square test gives a P 
value of 0.170 which is not statistically significant for the age distribution 
between the two groups. 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Cases Controls
Age range within Groups
31 - 40 yrs 41 - 50 yrs 51 - 60 yrs Above 60 yrs
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Cross tabs- SEX * Groups 
Crosstab 
  
Groups 
Total 
 
Cases Controls 
SEX F Count 15 16 31 
% within Groups 27.3% 29.1% 28.2% 
M Count 40 39 79 
% within Groups 72.7% 70.9% 71.8% 
Total Count 55 55 110 
% within Groups 100.0% 100.0% 100.0% 
 
 
 
Cases Controls 
Female 27.3% 29.1% 
Male 72.7% 70.9% 
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Chi-Square Tests 
  Value df 
Asymp. 
Sig.  
(2-sided) 
Exact 
Sig.  
(2-sided) 
Exact 
Sig.  
(1-sided) 
Pearson Chi-Square 
 
.045a 1 .832   
Continuity 
Correctionb 
0.000 1 1.000   
Likelihood Ratio 
 
.045 1 .832   
Fisher's Exact Test 
 
   1.000 .500 
N of Valid Cases 110     
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is  
    15.50. 
 
b. Computed only for a 2x2 table 
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0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Cases Controls
Gender within Groups
Female Male
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5000.0
5500.0
6000.0
6500.0
7000.0
7500.0
8000.0
8500.0
Cases Controls
Total count/cm
 
Total count/cm 
Cases 8106.4 
Controls 7551.5 
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4000.0
4200.0
4400.0
4600.0
4800.0
5000.0
5200.0
5400.0
5600.0
5800.0
6000.0
Cases Controls
Neutrophil count
 
Neutrophil count 
Cases 5873.0 
Controls 5019.8 
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1000.0
1100.0
1200.0
1300.0
1400.0
1500.0
1600.0
1700.0
1800.0
1900.0
Cases Controls
Lymphocyte count
 
Lymphocyte count 
Cases 1673.4 
Controls 1803.3 
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0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
Cases Controls
Ejection Fraction %
 
Ejection Fraction % 
Cases 37.0 
Controls 61.2 
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0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
Cases Controls
Neutrophil/Lymphocyte ratio
 
Neutrophil/Lymphocyte ratio 
Cases 3.62 
Controls 2.87 
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Neutrophil/Lymphocyte ratio * Groups 
 
Crosstab 
  
Groups 
Total 
Cases Controls 
Neutrophil/ 
Lymphocyte ratio 
</= 3.5 Count 16 46 62 
 
% within 
Groups 
 
29.1% 83.6% 56.4% 
> 3.5 Count 39 9 48 
 
% within 
Groups 
 
70.9% 16.4% 43.6% 
Total 
Count 55 55 110 
% within 
Groups 
100.0% 100.0% 100.0% 
 
 
Cases Controls 
</= 3.5 29.1% 83.6% 
> 3.5 70.9% 16.4% 
 
55 
 
 
 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Cases Controls
Neutrophil/Lymphocyte ratio within  Groups
<= 3.5 > 3.5
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Chi-Square Tests 
  Value df 
Asymp. 
Sig.  
(2-sided) 
Exact 
Sig.  
(2-sided) 
Exact 
Sig.  
(1-sided) 
Pearson Chi-Square 
 
33.266a 1 .0005   
Continuity 
Correctionb 
 
31.085 1 .000   
Likelihood Ratio 
 
35.358 1 .000   
Fisher's Exact Test 
 
   .000 .000 
Linear-by-Linear 
Association 
 
32.964 1 .000   
N of Valid Cases 110     
 
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 
24.00. 
 
b. Computed only for a 2x2 table 
 
  
  
 
 
 
 
DISCUSSION 
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DISCUSSION 
 Complete blood count is a cheap, routine and practical laboratory 
test that gives us important information about the patient’s formed blood 
components. Routine complete blood counts may be useful in diagnosis 
and prognosis of many diseases. NLR is measured by dividing the 
number of neutrophils by the number of lymphocytes. NLR is an 
indicator of systemic inflammation. Inflammation plays a significant role 
in the body's combat against various noxious insults and is important in 
the development and progression of various diseases. Even when the total 
WBC count is in the normal range, NLR has been demonstrated to play a 
predictive role in the prognosis of chronic and acute inflammatory 
processes. A recent meta-analysis depicts that an elevated NLR is an 
independent factor associated with poorer overall survival in many solid 
tumours.  
 An elevated NLR may be associated with  
 renal or hepatic dysfunction 
  diabetes mellitus 
  abnormal thyroid function 
  hypertension 
  metabolic syndrome 
  hematological malignancies 
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 malignancy 
  preceding history of local or systemic infection 
  inflammatory diseases 
 some medications 
 There is substantial evidence from various studies that 
inflammation plays a critical role in the atherosclerotic process, from its 
initiation, progression, plaque destabilization, triggering of an acute 
coronary event, and infarction size, to recovery after AMI. It has been 
postulated that the greater the inflammatory response during the acute 
phases of AMI, the greater the proinflammatory activity during chronic 
(stable) phases of the disease. Several inflammatory biomarkers such as 
C-reactive protein, lipoprotein-associated phospholipase A2, neutrophil 
lymphocyte ratio and platelet lymphocyte ratio have been identified as 
important for risk stratification after AMI. The circulating white blood 
cell (WBC) count and differential counts are simple, inexpensive tests, 
and readily available inflammatory markers that have been associated 
with adverse events in patients with acute coronary syndrome. 
 In our study, we have divided the patients getting admitted to the 
intensive coronary care unit into 2 groups 
 Cases     - patients with acute STEMI with heart failure  
 Controls- patients with acute STEMI without heart failure 
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 It is our routine practice in our hospital that a blood sample will be 
drawn on admission in all patients getting admitted to the ICCU and this 
is done usually within the first hour of admission. At KMC on an average 
4 cases of AMI per day gets admitted with 40% developing heart failure. 
To get 55 cases of heart failure it would require roughly 2 months.110 
cases of acute STEMI (55 with heart failure and 55 without heart failure) 
are required to identify the association between elevated NLR and heart 
failure in acute STEMI at 95% confidence interval and when the 
percentage of acute STEMI without heart failure with elevated NLR is 
46% and the difference between the two is 30%.  
 Among the entire sample 79 were males and 31 were females. In 
our study we encountered an increased frequency of acute STEMI in the 
male population. The minimum age encountered was 35 years and the 
maximum age was 70 years. We divided the age groups in ranges of ten 
and found that nearly 60% of patients were in their fifth decade of life. . 
The mean age of the affected female was 55 with a standard deviation of 
3.6 years. The mean age of the affected male was 51 years with a 
standard deviation of 7.1 years. 
 An analysis of the group statistics between the two groups reveals 
that the mean age of the patients among the cases is 53.65+/- 6.43. The 
mean age of the patients among the control group is 51.2+/- 6.59. A 
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statistical analysis of the distribution of various age ranges between the 
two groups was also almost similar ensuring comparability between the 
two groups. A Pearsons Chi-Square test to assess the significance of age 
distribution between the two groups in the age category did not achieve 
statistical significance. (P value 0.170). 
 The gender distribution between the two groups was also similar 
with 27.3% females in the test and 29.1% females in the control group. 
The males constituted 72.7% in the test group and 70.9% in the control 
group. A Pearsons Chi-Square test to assess the significance of sex 
distribution between the two groups in the sex category did not achieve 
statistical significance. (P value 0.832). 
 The ejection fraction of the patients in the two groups is 
significant. The mean EF is 37+/- 7.16 in the test group with heart failure. 
The mean EF is 61+/-4.28 in the control group without heart failure. The 
unpaired t-test showed a highly significant difference with a P value of 
0.0005. 
 The mean neutrophil count of the cases was 5873 with a standard 
deviation of 1029. The mean neutrophil count of the control group was 
5019.8 with a standard deviation of 905.59.  
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 Similarly the mean lymphocyte count of the test group was 
1673.38 with a standard deviation of 392. The mean lymphocyte count of 
the control group was 1803.25 with a standard deviation of 467. 
 The mean neutrophil to lymphocyte ratio in the control group was 
2.868 with a standard deviation of 0.58.This falls well within the normal 
range of NLR among the controls. The mean NLR of the test group was 
3.617 with a standard deviation of 0.73. The mean NLR of the test group 
i.e., for patients with acute STEMI and heart failure falls outside the 
normal rangee with majority of the patients having an elevated NLR. Our 
aim is to assess whether this is statistically significant between the two 
groups. This is done by using the unpaired t-test. 
 The results of the unpaired t-test for neutrophil count between the 
two groups shows high statistical significance with a P value of 0.0005. 
The lymphocte count between the two groups did not reach statistical 
significance as is evident from the P value of 0.117 in the unpaired t-test.  
 The NLR distribution between the two groups is highly statistically 
significant with a P value of 0.0005. This shows that neutrophils play an 
important role in the inflammatory process in the pathogenesis and 
subsequent development of heart failure in patients with acute STEMI. It 
is also seen that patients with an elevated NLR>3.5 are at risk of 
developing heart failure.  
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 We have also done a Pearsons Chi-Square test on categorical data 
by dividing patients with NLR <3.5 and those with NLR >/= 3.5 between 
the cases and controls. This achieved high statistical significance with a P 
value of 0.0005. 
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CONCLUSIONS 
The following important conclusions can be drawn from this study 
1. There is a statistically significant difference in the neutrophil count 
between those patients developing heart failure as compared to 
those without heart failure in patients with acute STEMI. 
2. An elevated on admission NLR >3.5 is associated with 
development of heart failure in patients with acute STEMI. 
3. An elevated on admission NLR will help for additional risk 
stratification of the patient so that these patients can be put under 
intensive surveillance for subsequent development of heart failure 
or other complications of acute STEMI. Thus NLR , which is easy 
to assess and inexpensive, may be a novel biomarker for assessing 
inflammation and identifying high risk for heart failure in acute ST 
elevation MI. NLR was inversely correlated with EF. 
4. Inflammation with altered yet not clearly elucidated immune 
response underlies development of complications in patients with 
acute STEMI. 
5. The role of low dose aspirin in addition to having antiplatelet 
action probably does have some anti-inflammatory activity 
accounting for its beneficial effect in patients with acute coronary 
syndrome 
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6. NLR, which is easy to assess and inexpensive, may be a novel 
biomarker for assessing inflammation and identifying high risk for 
heart failure in acute ST elevation MI. 
7. NLR was inversely correlated with EF and is an independent 
predictor of heart failure in acute STEMI. 
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LIMITATIONS 
 As is evident from our discussion in the literature review this study 
may not be applicable to patients with acute STEMI having heart failure 
with preserved ejection fraction as we have not included these cases. 
Similarly we have not included patients with acute NSTEMI. Further 
studies on the relevance of elevated NLR are warranted in both the above 
groups. 
 
FUTURE PERSPECTIVES 
 Studies at the molecular level and genetic studies will help us to 
clearly understand the mechanisms underlying altered immune response 
and the development of complications in patients with acute coronary 
syndrome. 
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PROFORMA 
Name:                                                     Age/sex:                                             
Address:                                                  IPNO/OP NO: 
Comorbidities: 
Diagnosis: 
BMI: 
Personal history: 
 
QUESTIONNAIRE: 
Kuppusamy Socio economic State: 
Family History of DM / hypertension/ Heart disease 
Do you exercise regularly : 
 
INVESTIGATIONS: 
Complete blood count  
Renal function tests 
Liver function tests 
Lipid profile – Triglycerides and Total Cholesterol 
Fasting Blood sugar  
Electrocardiogram 
Echocardiogram 
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சுய ஒப்புதல் படிவம் 
ஆய்வு செய்யப்படும் தலைப்பு: 
 
இடம் : சபொது மருத்துவத்துவது துறை 
அரசு கீழ்பொக்கம் மருத்துவகல்லூொி மருத்துவமலை 
சென்லை 
 
பங்கு சபறுபவொின் சபயர் : 
பங்கு சபறுபவொின் வயது :  
பங்கு சபறுபவொின் எண் : 
 
மமமை குறிப்பிட்டுள்ள மருத்துவ ஆய்வின் விவரங்கள் எைக்கு 
விளக்கப்பட்டது. நொன் இவ்வொய்வில் தன்ைிச்லெயொக பங்மகற்கிமறன். 
எந்தகொரணத்திைொமைொ எந்த ெட்ட ெிக்கலுக்கும் உட்படொமல் நொன் 
இவ்வொய்வில் இருந்து விைகிக்சகொள்ளல்ைொம் என்றும் அறிந்து சகொண்மடன். 
இந்த ஆய்வு ெம்பந்தமொகமவொ,  இலத ெொர்ந்து மமலும் ஆய்வு 
மமற்சகொள்ளும் மபொதும் இந்த ஆய்வில் பங்குசபறும் மருத்துவர் என்னுலடய 
மருத்துவ அறிக்லககலள பொர்ப்பதற்கு என் அனுமதி மதலவயில்லை எை 
அறிந்து சகொள்கிமறன்.  இந்த ஆய்வின் மூைம் கிலடக்கும் தகவலைமயொ, 
முடிலவமயொ பயன்படுத்திக் சகொள்ள மறுக்கமொட்மடன். 
இந்த ஆய்வில் பங்கு சகொள்ள ஒப்புக் சகொள்கிமறன். இந்த ஆய்லவ 
மமற்சகொள்ளும் மருத்துவ அணிக்கு உண்லமயுடன் இருப்மபன் என்றும் 
உறுதியளிக்கிமறன். 
 
 
பங்மகற்பவொின் லகசயொப்பம்                              ஆய்வொளொின் லகசயொப்பம் 
 
இடம் : 
மததி : 
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PATIENT CONSENT FORM 
Study detail : “A case control study of association of neutrophil to 
lymphocyte ratio and heart failure in patients with Acute ST- elevation 
myocardial infarction” 
 
Study centre  :             GOVERNMENT ROYAPETTAH  
        HOSPITAL, CHENNAI 
Patients Name : 
Patients Age : 
Identification Number        : Patient may check ( √ ) in the boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation 
to it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this 
study. 
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I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in 
my health or well-being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
 
 
 
Signature/thumb impression:    
 
 
Patients Name and Address:                        place  date 
 
 
Signature of investigator :    
 
 
Study investigator’s Name :                     place date      
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PLAGIARISM CERTIFICATE 
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